WCWeishan Chen

Weishan Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weishan Chen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Ailan Yin

    Department of Obstetrics & Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

    1 shared publication
  • Bei Jia

    Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    1 shared publication
  • Fang Yang

    Department of Fetal Medicine and Prenatal Diagnosis, Zhujiang Hospital Southern Medical University Guangzhou China

    1 shared publication
  • Fenxia Li

    Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    1 shared publication
  • Fodi Huang

    Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    1 shared publication
  • Li-Yan Li

    Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University, Guangzhou, China

    1 shared publication

Latest Publications

  • Non-invasive prenatal test findings in 41,819 pregnant women: results from a clinical laboratory in southern China

    by Siping Liu, Qingxian Chang, Fang Yang, Yushuang Xu, Bei Jia, Ruifeng Wu, Liyan Li, Ailan Yin, Weishan Chen, Fodi Huang, et al.

    Background This paper evaluated the clinical utility of massively parallel sequencing-based non-invasive prenatal testing (NIPT) for detecting trisomy 21 (T21), T18, T13, sex chromosome aneuploidies (SCA), and rare chromosome aneuploidies (RCA) among the data collected by a clinical laboratory in southern China. Methods In a 3-year period between January 2017 and December 2019, over 40,000 pregnant women underwent NIPT clinical screening test for fetal T21, T18, T13, SCA, and RCA in our laboratory. NIPT samples were processed using the NextSeq CN500 platform. The positive results were confirmed by karyotyping, and chromosomal microarray analysis (CMA) or copy number variants (CNV) sequencing. Details of the pregnancy outcomes were collected via telephone interview. Results NIPT results were available for 41,819 cases; 691 positive cases were reported. The overall sensitivity for detection of T21, T18, T13, SCA, and RCA was 99.21, 100.00, 100.00, 98.55, and 100.00%, and the specificity was 99.95, 99.94, 99.98, 99.69, and 99.92%, respectively. The positive predictive values (PPVs) for detection of T21, T18, T13, SCA, and RCA were 85.62, 45.24, 40.00, 34.17, and 13.51%, respectively, and those for detection of 45,X, 47,XXY, 47,XXX, 47,XYY, and 46,XY(delX) 20.00, 59.18, 28.95, 61.54, and 25.00%, respectively. Regarding pregnancy outcomes, 92.38% of the pregnancies with confirmed aneuploidies were terminated, and 91.20% of those identified as having a false-positive result were carried to term. Among 252 unconfirmed cases, 24.60% of the pregnancies were terminated and 38.10% carried to term, while 37.30% declined interview. Conclusions NIPT is widely used to screen fetal aneuploidies based on its high sensitivity and specificity. However, in this study, the PPVs of NIPT in terms of detecting T18, T13, XO, XXX and RCA were < 50%. In addition, more than one-third of NIPT-positive women did not accept invasive prenatal diagnosis. Confirmatory diagnosis is strongly recommended for women with positive NIPT outcomes before any further decision is made.